Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 42Lung Neoplasms 18Melanoma 14Carcinoma, Hepatocellular 14Neoplasm Metastasis 13Esophageal Neoplasms 11Squamous Cell Carcinoma of Head and Neck 9Breast Neoplasms 8Head and Neck Neoplasms 6Esophageal Squamous Cell Carcinoma 6Rectal Neoplasms 5Colorectal Neoplasms 5Stomach Neoplasms 4Recurrence 4Neoplasms 4Carcinoma, Renal Cell 4Brain Neoplasms 4Uterine Cervical Neoplasms 3Triple Negative Breast Neoplasms 3Small Cell Lung Carcinoma 3Sarcoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Multiple Myeloma 3Cholangiocarcinoma 3Carcinoma, Transitional Cell 3Radiation Pneumonitis 2Pathologic Complete Response 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Oropharyngeal Neoplasms 2

Interventions

Oxaliplatin 2tislelizumab 1sintilimab 1donafenib 1Immunotherapy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Biliary Tract Carcinoma × Immunotherapy × Clear all
NCT06199882 2024-10-15

SBRT Sequential Surufatinib Combined With Immunotherapy for Biliary Tract Carcinoma

Zhejiang Cancer Hospital

Phase 2 Suspended
34 enrolled
Gastrointestinal

Biliary Tract Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡